Research programme: cancer therapy adjunct - ActoKine Therapeutics

Drug Profile

Research programme: cancer therapy adjunct - ActoKine Therapeutics

Alternative Names: Actokine-1; AK-1

Latest Information Update: 20 May 2010

Price : $50

At a glance

  • Originator ActoKine Therapeutics
  • Class Antineoplastics; Chemoprotectants; Cytokines; Radiation-sensitising agents; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Chemoprotection; Radioprotection

Most Recent Events

  • 20 May 2010 Preclinical development is ongoing in USA
  • 01 Jun 2006 This compound is still in active development
  • 13 May 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top